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Abstract
Introduction
The potential benefits of Mass Drug Administration (MDA) for malaria elimination are being
considered in several malaria endemic countries where a decline in malaria transmission
has been reported. For this strategy to work, it is important that a large proportion of the tar-
get population participates, requiring an in-depth understanding of factors that may affect
participation and adherence to MDA programs.
Methodology
This social science study was ancillary to a one-round directly observed MDA campaign
with dihydroartemisinin-piperaquine, carried out in 12 villages in rural Gambia between
June and August 2014. The social science study employed a mixed-methods approach
combining qualitative methods (participant observation and in-depth interviewing) and
quantitative methods (structured follow-up interviews among non-participating and non-
adhering community members).
Results
Of 3942 people registered in the study villages, 67.9% adhered to the three consecutive
daily doses. For the remaining villagers, 12.6% did not attend the screening, 3.5% was not
eligible and 16% did not adhere to the treatment schedule. The main barriers for non-partici-
pation and adherence were long and short-term mobility of individuals and specific
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subgroups, perceived adverse drug reactions and rumors, inconveniences related to the
logistics of MDA (e.g. waiting times) and the perceived lack of information about MDA.
Conclusion
While, there was no fundamental resistance from the target communities, adherence was
67.9%. This shows the necessity of understanding local perceptions and barriers to
increase its effectiveness. Moreover, certain of the constraining factors were socio-spatially
clustered which might prove problematic since focal areas of residual malaria transmission
may remain allowing malaria to spread to adjacent areas where transmission had been tem-
porarily interrupted.
Introduction
Approximately one-third of malaria endemic countries are pursuing strategies to achieve
malaria elimination [1–3]. However, attaining such an ambitious goal may not be feasible with
standard control strategies, e.g. Long-Lasting Insecticidal Nets (LLIN), Indoor Residual Spray-
ing (IRS) or larval source management [2,4]. Moreover, in low endemic countries and seasonal
malaria settings, a large proportion of Plasmodium falciparum infections are carried asymp-
tomatically and in low densities. Asymptomatic infected individuals, mostly undetectable by
microscopy or rapid diagnostic tests (RDT), can maintain transmission, particularly where
malaria transmission is low [1,5]. Mass drug administration (MDA), treating all individuals
regardless of their infection status, addresses this problem [1,5,6]. In addition, where malaria
transmission is seasonal, it is started every year by asymptomatically infected individuals who
in turn infect the vectors. By clearing such infections, MDA has the potential of preventing the
yearly malaria peak [1,2,6,7], which could have a greater impact than just treating malaria
patients attending health facilities [1,6,8]. Furthermore, as malaria risk is heterogeneous, result-
ing in pockets of transmission [9], MDA could be used to target these “hotspots” [10]. MDA is
currently the control or elimination strategy for other neglected tropical diseases (e.g. lym-
phatic filariasis, schistosomiasis, and onchocerciasis), despite controversy surrounding the
effectiveness and acceptability of such a strategy [1,2,7,11–16].
The effectiveness of MDA for malaria control or elimination, may be compromised by the
difficulty of achieving sufficient coverage either due to refusals or by poor treatment adherence
[1,5,6,8]. There are few reports and studies on factors influencing the participation in, and
adherence to, MDA campaigns targeting malaria [17]. The aim of this study was to explore the
motivations and circumstances for non-uptake and non-adherence of MDA with dihydroarte-
misinin-piperaquine (DHAPQ) (Eurartesim1) in rural Gambia.
Methods
Study site and population
The anthropological study was ancillary to a study looking at the dynamics of malaria trans-
mission and at factors determining its heterogeneity (referred to hereafter as the ‘Malaria
Transmission Dynamics study’). Twelve rural villages located in five regions of The Gambia,
namely West Coast River, North Bank, Lower River, Central River and Upper River Regions
(North Bank and South Bank), were included in the MDA campaign and provided the study
setting for the anthropological study. The selection of the study villages for the MDA campaign
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is described in Mwesigwa et al. [18]. It can be summarized as follows: it is based on a nation-
wide school survey and a follow-up malariametric survey in six villages surrounding the school
with highest seroprevalence of anti-malarial antibodies in each region. In 2013, the village with
the lowest and highest surrounding prevalence for each region were selected to be part of the
Malaria Transmission Dynamics study.
As part of this study inhabitants were actively followed up by monthly bleedings during the
rainy season carried out by fieldworkers and passive case detection at local health facilities. The
MRCG fieldworkers collected a blood sample for the detection of malaria infections by PCR,
and in case of symptomatic individuals a rapid diagnostic test (RDT) for the immediate detec-
tion of a malaria infection was performed.
Malaria transmission in The Gambia is highly seasonal (August to December) [9,19]. The
total population of the study villages was about 4,500 people, mainlyMandinka, Serahule,
Wolof and Fula, with the large majority being Muslim and practicing subsistence farming.
Remittances from family members living in Europe and America contributed to the livelihoods
of some families. Villages comprised compounds containing several households related by
kinship.
The implementation of MDA in the study setting
One round of directly observed MDA with DHAPQ (Eurartesim1)—a drugs with a prophylac-
tic functioning—was carried out from June to August 2014, before the beginning of the malaria
transmission season. It was preceded by sensitization meetings to inform the communities of
the MDA intervention and personal written consent. All DHAPQ doses were directly observed
for the three-day treatment by a team of nurses and fieldworkers from the Medical Research
Council Unit, The Gambia (MRCG), assisted by local village health workers (VHW) and com-
munity volunteers. Individuals with confirmed positive RDT, documented cardiac or renal
pathological conditions, pregnant women (all women15 years old were systematically
screened with a urine pregnancy test), infants< 5 kg, and adults> 75 years old were excluded
from the MDA. Participants with uncomplicated malaria and pregnant women were referred
to the government health facilities for the appropriate treatment; underweight children and
people> 75 years did not receive an alternative drug. This was the first MDA carried out in
these study villages.
Study design
Amixed-methods design was used for the social science study.
During the first phase, qualitative data were collected for independent analysis and to pre-
pare the quantitative strand. During the first qualitative strand, ethnographic research was con-
ducted in all study villages, with focused fieldwork during the MDA in two pairs of adjacent
villages (Njayel and Madina Samako in the Upper River Region south bank; Sare Wuro and
Gunjur Koto in the Upper River Region north bank). These two pairs of villages were theoreti-
cally selected to be observed during MDA, based on expected (i) lower participation/adherence
to the treatment and (ii) higher human mobility. Literature indicated the importance of these
variables for the success of MDA, and previous qualitative research by the researchers had
shown the presence of these factors in the four selected villages.
During the second strand of research, quantitative data were collected to confirm and quan-
tify results from the qualitative component. The quantitative phase was initiated when the list
documenting MDA uptake became available. Quantitative data were systematically collected
by administering a questionnaire among non-participating (did not take any medication) or
non-adhering (did not take all 3 doses) individuals in all twelve villages.
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Qualitative data
Data collection. Participant observation consisted of participating in everyday activities in
the communities and observing the sensitization and drug distribution during MDA. Reiter-
ated informal conversations with MRCG fieldworkers and community members, regardless of
their decision to participate, were carried out, leading to an in-depth understanding of more
sensitive topics such as social relationships and trust in MDA and the MRCG.
Interviews with community members were recorded and fully transcribed. These interviews
were carried out before, during and directly after MDA. When not possible and/or inappropri-
ate given the sensitive nature of the topic discussed, the conversation was not recorded imme-
diately but its content was written down immediately after the interview. Interviews were
mostly carried out in the local languages, namelyMadinka, Fula and Serahule. The question
guide focused on factors influencing MDA such as the informed consent procedures, mobility,
adverse drug reactions and perceptions of the trial.
Sampling. Following the principle of gradual selection, informants were theoretically
selected (in accordance with emerging results/theory) and categorized in relation to relevant
criteria (e.g. gender, age, socio-economic status, decision to participate and adhere). In addi-
tion, “snowball” sampling techniques—sampling using participants to identify additional
respondents—were used in order to increase confidentiality with respondents and consequent
reliability of the data [20].
Data analysis. In accordance with the research strategy, data analysis was a flexible and
iterative process. Preliminary data from the observations, informal conversations and inter-
views were collected and analyzed to inform the interview guide; in-depth interviews were then
conducted to confirm or refute temporary results until saturation was reached. Interviews were
systemized and analyzed with NVivo 10 Qualitative Analysis Software (QSR International Pty
Ltd. Cardigan UK).
Quantitative data
Data collection. Following the MDA, a questionnaire was administered to adults who did
not participate (did not go for screening) or did not complete the treatment (intake of 1 or 2
doses), focusing on potential barriers for participation and adherence. The questionnaire con-
sisted of a combination of open- and closed-ended questions.
Sampling. The sampling frame consisted of adult community members who did not par-
ticipate or adhere to the MDA as recorded by in the MDA trial registration list. People who
were not allowed to participate due to the MDA exclusion criteria were not included. Prelimi-
nary data of the MDA trial registration list showed that 63.7% of the people who did not take
the medication or did not adhere were minors, and 36.3% were adults. Every 4th adult person
on the list was selected, and respondents were re-visited 3 times before exclusion from the
quantitative study. Seventy-four adults from all villages were systematically selected from the
trial registration list that documented non-participation/non-adherence.
Data analysis. Quantitative data were double entered in Microsoft Excel and cleaned and
analyzed in SPSS (IBM SPSS Statistics 22). Frequency tables and cross-tables for the main out-
come variables were produced.
Ethical clearance
The Malaria Transmission Dynamics study, including MDA, received ethical approval by the
MRC Scientific Coordinating Committee and The Gambia Government/MRC joint Ethics
Committee (SCC number 1318). The social science study was approved by the MRC Scientific
Coordinating Committee and The Gambia Government/MRC joint Ethics Committee (SCC
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number 1319) and by the Institutional Review Board of the Institute of Tropical Medicine,
Antwerp, Belgium. The interviewers followed the Code of Ethics of the American Anthropo-
logical Association (AAA). People were informed about the social science research in commu-
nity sensitization meetings preparing the overall Malaria Transmission Dynamics study.
Before participating in the social science research, respondents were informed about project
goals, the topic and type of questions as well as their right to decline participation or to inter-
rupt the conversation at any time. Anonymity was guaranteed and confidentiality of interview-
ees assured by assigning a unique code number to each informant. Verbal instead of written
consent was preferred as requesting the subject’s signature could have been a potential reason
for mistrust.
Results
Participation and adherence to MDA
Among the 3942 people (including children, adults and elders) registered in the study villages,
87.4% (3445/3942) participated (agreed to be screened) and 67.9% (2675/3942) adhered to the
three consecutive doses (Table 1).
Among the 3445 people screened for the MDA, 96% (3306/3445) was eligible to participate
[4% was not eligible (139/3445)]. 77.7% (2675/3445) adhered to the three consecutive DHPAQ
doses while [18.3% (631/3445) did not (intake of 1 or 2 doses)] (Table 2).
A total of 74 adult individuals were included in the quantitative study, 49 of them had refused
the MDA and 25 had not completed the 3-day treatment (Table 3). The large majority of them
were of Fula ethnicity (60.6%) and women (56.8%) were slightly more represented (Table 4).
Reasons for non-participation or adherence
The main barriers for non-participation and non-adherence were long and short-term mobility
of individuals and specific subgroups, perceived adverse drug reactions and related rumors,
inconveniences related to the logistics of MDA (e.g. waiting times) and the perceived lack of
information about MDA (Tables 5 and 6).
Table 1. Participation and adherence to MDA among study population (N = 3942).
n %
Did not want to participate (not screened for MDA) 497 12.6
Did want to participate (screened for MDA) 3445 87.4
- Intake of 1 dose 189 4.8
- Intake of 2 doses 442 11.2
- Intake of 3 doses 2675 67.9
- Not eligible 139 3.5
doi:10.1371/journal.pone.0148627.t001
Table 2. Adherence to MDA among people screened (N = 3445).
n %
- Intake of 1 dose 189 5.5
- Intake of 2 doses 442 12.8
- Intake of 3 doses 2675 77.7
- Not eligible 139 4.0
doi:10.1371/journal.pone.0148627.t002
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Mobility
The most common reason for non-participation was human mobility (32.9%) (Table 5).
Among non-adherent respondents this was the second major barrier for full participation
(20%) (Table 6). Mobility was understood as long term, seasonal or routine human population
movements over considerable distance between and within countries, hence it does not include
people working on the farms or staying at schools who could have reached the MDA distribu-
tion point. The qualitative study indicated that different mobility patterns influenced MDA in
distinct ways. Potential participants were (i) absent during the MDA; (ii) not documented in the
baseline census and consequently not actively identified during the MDA; (iii) absent during
community sensitization meetings; and, (iv) temporarily not residing in the villages. Specific
mobility patterns were: (i) cross-border movements between The Gambia and Senegal, such as
Table 3. Participation and adherence to MDA among study participants quantitative strand (N = 74).
n %
Intake of 0 doses 49 66.2
Intake of 1 dose 12 16.2
Intake of 2 doses 13 17.6
doi:10.1371/journal.pone.0148627.t003
Table 4. Socio-demographic characteristics of study participants quantitative strand (N = 74).
n %
Gender
Male 32 45.9
Female 42 56.8
Ethnicity
Fula 45 60.6
Madinka 8 10.8
Jola 5 6.8
Tilibonka 4 5.4
Serahule 3 4.1
Other ethnic groups 5 8.2
Missing information 3 4.1
doi:10.1371/journal.pone.0148627.t004
Table 5. Reasons for non-participation in MDA (multiple answers possible) (N = 49).
n %
Mobility 23 32.9
Perceived side effects 8 11.4
Lack of trust 13 18.6
Waiting time 13 18.6
Drug characteristics 2 2.9
Public pregnancy test 2 2.9
Misunderstanding MDA 5 7.1
Compound/Household head did not allow 3 4.2
Missing information 1 1.4
Total answers 70 100
doi:10.1371/journal.pone.0148627.t005
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people working or studying in Senegal, but frequently returning to their home village in The
Gambia, or Senegalese citizens migrating temporarily to work on farms in The Gambia during
the rainy season; (ii) rural to urban movements for temporary and permanent work and health
care, particularly along the Gambian coast; (iii) rural to rural movements, such as men looking
for job opportunities in the agricultural sector just before and during the rainy season; and, (iv)
cattle herding, especially among male Fula herders in search of grazing land for their cattle.
Perceived side effects
While fear of perceived side effects was a factor influencing initial participation (11.4%)
(Table 5), it was the most important barrier for non-adherence (42.8%) (Table 6). The most
commonly reported perceived side effects were fever, stomach pain, skin rashes, diarrhea, diz-
ziness, fatigue (or general malaise) and vomiting. Some people interpreted these as normal
effects of antimalarials, demonstrating DHAPQ ‘worked’. Coping mechanisms for perceived
minor side effects included taking the medicine during the evening so symptoms would appear
during sleep or simply stopping the treatment.
‘When I took the drugs it affects me a lot because when I am in bed it seems like the bed is
moving. It caused certain things that also my mother had never experienced before. And I had
headache, vomiting and high temperature. It took me two days to recover, I did not go out so
due to that, I took the drug once.’
(Housewife, Njayel)
As the MDA was conducted at the beginning of the rainy season during intense agricultural
activity, the perceived side effects would also lead to non-adherence as people feared it pre-
vented them from working in the fields.
Respondents rarely mentioned serious side effects, e.g. extreme tiredness, loss of conscious-
ness and ‘talking nonsense’ (hallucinations), as reaction to MDA. When people did mention
serious side effects, qualitative data showed that participants and their family members stopped
taking the required doses. People experiencing side effects did not always contact the MRCG
nurses for medical care.
Trust
For 18.6% of non-participating respondents, the lack of trust in the MDA campaign was a bar-
rier for participation (Table 5). Interestingly, it does not show in the quantitative data about
the non-adherent populations. Nevertheless, qualitative data indicates that upcoming rumors
Table 6. Reasons non-adherence to MDA (multiple answers possible) (N = 25).
n %
Mobility 7 20
Perceived side effects 15 42.8
Waiting time 4 11.4
Drug characteristics 1 2.9
Public pregnancy test 2 5.7
Misunderstanding MDA 4 11.4
Compound/Household head did not allow 1 2.9
Missing information 1 2.9
Total answers 35 100
doi:10.1371/journal.pone.0148627.t006
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regarding the side effects had an effect on people’s adherence. Qualitative data showed that
fears about the side effects turned into rumors regarding the safety of the drug affecting the
uptake of MDA in some compounds in certain villages. Examples of elements that fueled fears
were rumors that the drug was still in trial; the MDA team did not take the drugs themselves,
and the requirement to sign or thumb print the informed consent sheet which was perceived
not to safeguard people’s interests but to assure that the MRCG could not be held responsible
in case of serious adverse events.
‘The only skepticism that I have is that you want to give me medication and you want me to
sign. In case I do sign for it and a very bad adverse reaction happens to me, how can I manage
that because I have already accepted taking the pills?’
(Male farmer, Bessi)
Some people were distrustful about the intentions of the MRCG because they feared the
recurrent blood sampling required for the main Malaria Transmission Dynamics study (once
per month during the previous 6 months of the rainy season). Previous frictions and political
disputes among different compounds within the village would exacerbate discussions around
the safety of the drug. Few female respondents reported they were not able to participate
(4.2%) (Table 5) or adhere (5.7%) (Table 6) because their compound head or husband did not
allow them. Qualitative research showed that the disapproval of the compound head or hus-
band was also a constraining factor for children and adolescents. This disapproval was usually
due to pre-existing disagreements with the MDA team or a general distrust towards to the
MRCG. Nevertheless, most community members trusted the MRCGMDA fieldworkers as
they had resided and provided free health care in the study villages during the previous malaria
season.
Inconveniences related to MDA procedures
For 18.6% of respondents, waiting time was a barrier for participation (Table 5); and for 11.4%
of the respondents it influenced their decision to not complete the medication (Table 6).
Observations revealed that the procedure of consenting, having their body weight and temper-
ature measured, and, when relevant, a pregnancy test and a RDT performed before receiving
the first drug dose, resulted in long waiting times, and in some villages to discussions about
who should receive the drugs first: whether it should be children who had to go to school or
men herding their cattle or farming the land. In addition, because treatment had to be taken on
an empty stomach, some individuals were asked to return home and come back later, regard-
less of the time they had been waiting. MDA participants, especially children, complained
about the size and the bitter taste of DHAPQ tablets which made it difficult to swallow, and
consequently failed to participate or adhere (Tables 5 and 6).
Finally, qualitative data showed that most pregnant women did not come for screening. In
The Gambia, women intentionally conceal their pregnancies in order to avoid gossip and evil
spirits. In particular, pregnant adolescents, unmarried women and older women, who feel
shameful of their pregnancies due to their social position, would prefer not to participate.
Despite the assurance that pregnancy testing was carried out privately, some women preferred
not to go or to disrupt their screening (Table 5).
Misunderstanding MDA
The large majority of non-participating (36.7%) (Table 7) and non-adhering individuals (52%)
(Table 8) thought the MDA aimed at preventing malaria (Tables 5 and 6). Certain respondents
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mentioned during the interview that MDA aimed at curing or preventing diseases such as
tuberculosis, asthma, heart disease, hypertension and general health problems. Other people
stated they did not know they were eligible to participate.
Discussion
While several studies have looked into community factors relating to MDA for neglected tropi-
cal diseases [12,14,15], less is known about the potential barriers at community level for MDA
with the objective of interrupting malaria transmission [7]. With a growing interest in MDA
for malaria in elimination settings, there is the need to understand factors that affect the differ-
ent implementation stages: screening, participation and adherence. Within the Malaria Trans-
mission Dynamics study, MDA reached 67.9% of the study population after accounting for
people who did not go for screening, were not eligible and those that did not adhere (Table 1).
This research shows that a single way of implementing MDA has variable results in different
communities. As Krentel & Augner [14] discussed previously on lymphatic filariasis elimina-
tion, willingness to participate and to adhere to different drug doses is a highly situational deci-
sion. It is influenced by the interaction of demographic features, local health perceptions, the
organization of MDA and other contextual factors. While some of these elements are health
related (local health perceptions, fears surrounding pregnancy and drug characteristics), other
factors are not. Non-health related factors seemed to be more prevalent and important for deci-
sion-making in the Gambian context and included mobility, trust and rumors, trial logistical
factors, misunderstandings about MDA and the influence of the compound head/husband on
the decision-making process.
The implicit assumption in many interventions is that rural villages are static entities, and
as such mobile people and groups are often excluded from health interventions, explicitly
because they do not conform to inclusion criteria (living permanently in a village) or implicitly
because they are not present during the intervention. The exclusion of these mobile people and
groups in MDA is problematic since they constitute a potential source of infection [21,22].
Table 8. Knowledge about objective MDA of non-adherents to MDA (N = 25).
n %
Objective MDA
Improve health 2 8
Prevention of sickness 8 32
Prevention of malaria 13 52
Treat malaria 1 4
I don't know 1 4
doi:10.1371/journal.pone.0148627.t008
Table 7. Knowledge about objective MDA of non-participants MDA (N = 49).
n %
Objective MDA
Improve health 11 22.5
Treat sickness 1 2
Prevention of sickness 8 16.3
Prevention of malaria 18 36.7
Treat malaria 4 8.2
I don't know 7 14.3
doi:10.1371/journal.pone.0148627.t007
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As reported in other contexts, the process of informed consent does not always achieve par-
ticipants’ understanding of the trial in order to make a free and informed decision [23].
Although MRCG staff organized community meetings, and individual informed consent was
obtained from study participants, people who did not participate or did not adhere, did not
always understand the MDA’s objectives and procedures.
The origin and circulation of rumors, and how to target them, requires contextualized
knowledge, especially for intervention targeting asymptomatic carriers. Taking medication
when you are not sick requires trust in the institutions implementing the public health cam-
paign [24–26]. The MRCG has been present in The Gambia for almost 70 years, and many
people benefited of it. Trust in the MDA strategy was therefore based on previous positive
interactions with the institution (MRCG) and its staff that resided in the study villages. Field-
workers interact on a daily basis with researchers and community members [27] and their
behavior is important for the success of the MDA. Their actions can limit MDA uptake, but
they also can assist in enabling MDA by reassuring people and providing information in case
of side effects. While the overall public trust in the MRCG is strong in the communities, a few
people are skeptical about the MRCG apparently mostly due to fears surrounding recurrent
blood sampling although detailed research on the generation of rumors and reasons behind
them were outside the scope of this study. While, trust does not seem to directly influence peo-
ple’s adherence based on the quantitative data, the small group of people who are skeptical
about the MRCG, can have an influence on spread of rumors when side effects appear.
Although the qualitative data demonstrated that side effects did lead to fear and rumors about
the medication among the people who did not adhere, quantitative methods did not pick up on
this sensitive topic as can be expected due to the formality of the data collection.
Conclusion
The decision-making process to participate in MDA is influenced by a combination of health
and especially non-health related factors that are highly heterogeneous and could consequently
result in not covering a large social or spatial sub-group of the population. Even with a coverage
of>80%, the spatial and social clustering of these sub-groups might allow focal areas of resid-
ual transmission to remain. Formative [28] social science research before, during and after
MDA creates a better understanding of structural local constraints and concerns and can even-
tually provide the opportunity to contextualize the intervention and maximize potential partic-
ipants’ free and informed decision to participation and adherence.
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